The Claim
Epicardial fat in patients with cardiovascular disease releases higher concentrations of RBP4, ADIPOQ, FABP4, ICAM-1, and MPO than subcutaneous fat, contributing to systemic metabolic and inflammatory signaling associated with cardiovascular disease progression.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with cardiovascular disease, fat surrounding the heart releases more of five specific signaling molecules than fat under the skin, and these molecules are involved in metabolic and inflammatory processes linked to the disease.
See the scientific wording
Epicardial fat in patients with cardiovascular disease releases higher levels of RBP4, ADIPOQ, FABP4, ICAM-1, and MPO compared to subcutaneous fat, suggesting that epicardial fat may contribute to systemic metabolic and inflammatory signaling relevant to cardiovascular disease progression.
The fat surrounding the heart releases more proteins that disrupt metabolism and trigger inflammation than fat under the skin. These proteins enter the bloodstream, damage blood vessel lining, promote plaque buildup, and activate immune cells that worsen tissue injury, accelerating heart disease.
What the research says
1 studyThe study found that the fat around the heart in heart disease patients releases more inflammation and metabolism-related proteins than the fat under the skin, which helps explain why this fat might make heart disease worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.